-
If you purchased shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), you have certain options and you should contact the Shareholders Foundation, Inc.
-
To have your information reviewed for options and to receive notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Investigation Overview
July 25, 2016 - On July 14, 2016, ZIOPHARM Oncology Inc revealed that a brain cancer patient in an ongoing clinical trial had died after being treated with Ad-RTS-hIL-12, the Company's experimental gene therapy. A Ziopharm spokesman commented that ZIOPHARM Oncology Inc had not yet informed the U.S. Food and Drug Administration of the death. ZIOPHARM Oncology Inc then disclosed a secon...
You must register (for free) or login to view the entire investigation.
